Prof. Zhihao Lu 鲁智豪
Chief Physician, Professor
Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Immunotherapy, targeted therapy, and comprehensive treatment for esophageal, gastric, colorectal, hepatobiliary, pancreatic, and other digestive system tumors.
Dr. Lu holds a PhD in Oncology from Peking University and completed postdoctoral training at Johns Hopkins Hospital. With nearly 20 years of experience in diagnosing and treating digestive tract tumors, Dr. Lu specializes in drug and comprehensive therapies, including chemotherapy, molecular targeted therapy, and immunotherapy for advanced cancers. Dr. Lu has led or participated in over ten national and provincial research projects and dozens of clinical trials.
Professional roles
- Editor-in-Chief, Electronic Journal of Comprehensive Oncology
- Member, Precision Therapy Committee, China Anti-Cancer Association
- Vice Chair, Esophageal Cancer Committee, Beijing Cancer Prevention and Control Association
- Chair, Young Physicians Committee on Esophageal Cancer, Beijing Cancer Prevention and Control Association
Name order: in Chinese the family name comes first (Lu Zhihao). Papers usually list the name as Zhihao Lu or Lu Z.
Selected publications
94 papers on PubMed matched by name and affiliation; 28 as first or senior author since 2016. Most recent first- or senior-author papers:
- JAMA, 2026 (first author): Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial. PubMed 43018949
- NPJ Vaccines, 2026 (senior author): Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma. PubMed 42315874
- Chin J Cancer Res, 2025 (senior author): Development and validation of a clinical risk-prediction model for immune checkpoint inhibitor-related pneumonitis in patients with gastrointestinal cancer based on four machine learning algorithms. PubMed 41523839
- J Clin Oncol, 2025 (first author): Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma". PubMed 40934453
- Nat Med, 2025 (senior author): A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. PubMed 40640393
- J Clin Oncol, 2025 (first author): NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial. PubMed 40179324
- Cancer Immunol Immunother, 2025 (first author): Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies. PubMed 40056201
- Cancer Immunol Immunother, 2025 (senior author): An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma. PubMed 39998564
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion